Plasma Ndel1 enzyme activity is reduced in patients with schizophrenia - A potential biomarker?

Journal of Psychiatric Research

Volumn 47, Issue 5, 2013, Pages 657-663

  Gadelha, Ary ^a   Machado, Mauricio F M ^a   Yonamine, Camila M ^a   Sato, João R ^b   Juliano, Maria A ^a   Oliveira, Vitor ^a   Bressan, Rodrigo A ^a   Hayashi, Mirian A F ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

Biomarker; Enzyme activity; Neuropeptide; Oligopeptidase; Plasma; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; CHLORPROMAZINE; ENZYME; NUCLEAR DISTRIBUTION ELEMENT LIKE 1 ENZYME; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK; SCHIZOPHRENIA; STUDENT T TEST; TOBACCO DEPENDENCE;

EID: 84875236501     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.01.009     Document Type: Article

References (47)

1. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genetics 2008, 40:827-834.
2. Andreassen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rational for consensus. American Journal of Psychiatry 2005, 162:441-449.
3. Bauer R., Mayr A., Lederer W., Needham P.L., Kilpatrick I.C., Fleischhacker W.W., et al. Further evidence that behavioral tests and neuropeptide mRNA and tissue level alterations can differentiate between typical and atypical antipsychotic drugs. Neuropsychopharmacology 2000, 23:46-55.
4. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biological Psychiatry 2001, 50:856-872. [Review].
5. Boules M., Shaw A., Fredrickson P., Richelson E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 2007, 21:13-23. [Review].
6. Brandon N.J., Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nature Reviews Neuroscience 2011, 12:707-722.
7. Brandon N.J., Handford E.J., Schurov I., Rain J.C., Pelling M., Duran-Jimeniz B., et al. Disrupted in schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Molecular and Cellular Neuroscience 2004, 25:42-55.
8. Breen G., Harwood A.J., Gregory K., Sinclair M., Collier D., St Clair D., et al. Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients. Bipolar Disorders 2004, 6:156-161.
9. Bressan R.A., Chaves A.C., Shirakawa I., de Mari J. Validity study of the Brazilian version of the Calgary depression scale for schizophrenia. Schizophrenia Research 1998, 32(1):41-49.
10. Burdick K.E., Kamiya A., Hodgkinson C.A., Lencz T., DeRosse P., Ishizuka K., et al. Elucidating the relationships between DISC1, Ndel1 and Nde1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Human Molecular Genetics 2008, 17:2462-2473.
11. Cáceda R., Kinkead B., Nemeroff C.B. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?. Seminars in Clinical Neuropsychiatry 2003, 8:94-108. [Review].
12. Camargo A.C., Caldo H., Emson P.C. Degradation of neurotensin by rabbit brain endo-oligopeptidase A and endo-oligopeptidase B (proline-endopeptidase). Biochemical and Biophysical Research Communications 1983, 116:1151-1159.
13. Camargo L.M., Collura V., Rain J.C., Mizuguchi K., Hermjakob H., Kerrien S., et al. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Molecular Psychiatry 2007, 12:74-86.
14. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., et al. Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007, 130:1146-1158.
15. Greiner M., Pfeiffer D., Smith R.D. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Preventive Veterinary Medicine 2000, 45:23-41.
16. Gruber S.H., Angelucci F., Nomikos G.G., Mathé A.A. Effects of olanzapine on extracellular concentrations and tissue content of neurotensin in rat brain regions. European Neuropsychopharmacology 2011, 21:918-927.
17. Guerreiro J.R., Winnischofer S.M., Bastos M.F., Portaro F.C., Sogayar M.C., Camargo A.C., et al. Cloning and characterization of the human and rabbit NUDEL-oligopeptidase promoters and their negative regulation. Biochemical and Biophysical Research Communications 2005, 1730:77-84.
18. Hayashi M.A., Portaro F.C., Tambourgi D.V., Sucupira M., Yamane T., Fernandes B.L., et al. Molecular and immunochemical evidences demonstrate that endooligopeptidase A is the predominant cytosolic oligopeptidase of rabbit brain. Biochemical and Biophysical Research Communications 2000, 269:7-13. Erratum in: Biochemical and Biophysical Research Communications 2000;272:309.
19. Hayashi M.A., Portaro F.C., Camargo A.C. Cytosolic oligopeptidases: features and possible physiopathological roles in the immune and nervous systems. Current Medicinal Chemistry Central Nervous System Agents 2004, 4:269-277.
20. Hayashi M.A., Portaro F.C., Bastos M.F., Guerreiro J.R., Oliveira V., Gorrão S.S., et al. Inhibition of NUDEL (nuclear distribution element-like)-oligopeptidase activity by disrupted-in-schizophrenia 1. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:3828-3833.
21. Hayashi M.A., Guerreiro J.R., Charych E., Kamiya A., Barbosa R.L., Machado M.F., et al. Assessing the role of endooligopeptidase activity of Ndel1 (nuclear-distribution gene E homolog like-1) in neurite outgrowth. Molecular and Cellular Neuroscience 2010, 44:353-361.
22. Juliano L., Chagas J.R., Hirata I.Y., Carmona E., Sucupira M., Oliveira E.S., et al. A selective assay for endooligopeptidase A based on the cleavage of fluorogenic substrate structurally related to enkephalin. Biochemical and Biophysical Research Communications 1990, 173:647-652.
23. Kamiya A., Kubo K., Tomoda T., Takaki M., Youn R., Ozeki Y., et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nature Cell Biology 2005, 7:1167-1178. Erratum in: Nature Cell Biology 2006;8:100.
24. Kamiya A., Tomoda T., Chang J., Takaki M., Zhan C., Morita M., et al. DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1. Human Molecular Genetics 2006, 15:3313-3323.
25. Kinkead B., Nemeroff C.B. Neurotensin, schizophrenia, and antipsychotic drug action. International Review of Neurobiology 2004, 59:327-349. [Review].
26. Kinkead B., Nemeroff C.B. Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurological Disorders-Drug Targets 2006, 5:205-218.
27. Lawandi J., Gerber-Lemaire S., Juillerat-Jeanneret L., Moitessier N. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. Journal of Medicinal Chemistry 2010, 53:3423-3438.
28. Levine S.Z., Rabinowitz J. Revisiting the 5 dimensions of the positive and negative syndrome scale. Journal of Clinical Psychopharmacology 2007, 27:431-436.
29. Lima M.S., Soares B.G., Paoliello G., Machado Vieira R., Martins C.M., Mota Neto J.I., et al. The Portuguese version of the clinical global impression-schizophrenia scale: validation study. Revista Brasileira de Psiquiatria 2007, 29:246-249.
30. Lipska B.K., Peters T., Hyde T.M., Halim N., Horowitz C., Mitkus S., et al. Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Human Molecular Genetics 2006, 15:1245-1258.
31. Maes M., Goossens F., Scharpé S., Calabrese J., Desnyder R., Meltzer H.Y. Alterations in plasma prolylendopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Research 1995, 58:217-225.
32. Männisto P.T., Venäläinen J., Jalkanen A., García-Horsman J.A. Prolyloligopeptidase: a potential target for the treatment of cognitive disorders. Drug News & Perspectives 2007, 20:293-305. [Review].
33. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., Dorsa D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. Journal of Pharmacology and Experimental Therapeutics 1994, 271:460-471.
34. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A., et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics 2000, 9:1415-1423.
35. Millar J.K., James R., Brandon N.J., Thomson P.A. DISC1 and DISC2: discovering and dissecting molecular mechanisms underlying psychiatric illness. Annals of Medicine 2004, 36:367-378. [Review].
36. Moens L.N., De Rijk P., Reumers J., Van den Bossche M.J., Glassee W., De Zutter S., et al. Sequencing of DISC1 pathway genes reveals increased burden of rare missense variants in schizophrenia patients from a northern Swedish population. PLoS One 2011, 8:e23450.
37. Myöhänen T.T., Venäläinen J.I., García-Horsman J.A., Piltonen M., Männistö P.T. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues. Histochemistry and Cell Biology 2008, 130:993-1003.
38. Nicodemus K.K., Callicott J.H., Higier R.G., Luna A., Nixon D.C., Lipska B.K., et al. Evidence of statistical epistasis between DISC1, CIT and NDEL1 impacting risk for schizophrenia: biological validation with functional neuroimaging. Human Genetics 2010, 127:441-452.
39. Ozeki Y., Tomoda T., Kleiderlein J., Kamiya A., Bord L., Fujii K., et al. Disrupted-in-schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:289-294. Erratum in: Proceedings of the National Academy of Sciences of the United States of America 2004;101:13969.
40. Prus A.J., Huang M., Li Z., Dai J., Meltzer H.Y. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Research 2007, 1184:354-364.
41. Quinto B.M., Juliano M.A., Hirata I., Carmona A.K., Juliano L., Casarini D.E. Characterization of a prolyl endopeptidase (kininase) from human urine using fluorogenic quenched substrates. The International Journal of Biochemistry & Cell Biology 2000, 32:1161-1172.
42. Sasaki S., Mori D., Toyo-oka K., Chen A., Garrett-Beal L., Muramatsu M., et al. Complete loss of Ndel1 results in neuronal migration defects and early embryonic lethality. Molecular and Cellular Biology 2005, 25:7812-7827.
43. Sawa A., Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science 2002, 296:692-695.
44. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J.P., Guest P.C., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010, 5:39-47.
45. Schwarzer C. 30 Years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacology & Therapeutics 2009, 123:353-370.
46. Stefansson H., Rujescu D., Cichon S., Pietiläinen O.P., Ingason A., Steinberg S., et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008, 455:232-236.
47. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of General Psychiatry 2003, 60:1187-1192.